Summary
This research project investigates the role of sleep disruption following acute organophosphate (OP) intoxication in the development of seizures and cognitive deficits, and proposes to test an FDA-approved drug, Lemborexant, as a therapeutic intervention.
What they want
The project aims to evaluate the natural history of sleep architecture changes in the days-to-months following acute intoxication with the OP diisopropylfluourophosphate (DFP), elucidate mechanisms linking greater sleep disturbance to prolonged cognitive and seizure disorders, identify changes in sleep-wake phenotypes in the initial hours-to-days post-intoxication as biomarkers to predict the extent of cognitive and seizure outcomes, and test early and delayed interventions with the FDA-approved dual-orexin receptor antagonist (DORA) Lemborexant to improve sleep phenotypes and protect against or reduce seizure frequency, duration, and improve cognitive outcomes. This collaborative proposal addresses four topic areas related to the CounterACT PAR-24-030.
Technical requirements
- Intervention with FDA-approved dual-orexin receptor antagonist (DORA) Lemborexant
